Hill­house re­casts spot­light on Chi­na's biotech scene with $160M round for Shang­hai-based an­ti­body mak­er

Al­most two years af­ter first buy­ing in­to Genor Bio­phar­ma’s pipeline of can­cer and au­toim­mune ther­a­pies, Hill­house Cap­i­tal has led a $160 mil­lion cash in­jec­tion to push the late-stage as­sets over the fin­ish line while con­tin­u­ing to fund both in­ter­nal R&D and deal­mak­ing.

The Se­ries B has land­ed right around the time Genor would have list­ed on the Hong Kong stock ex­change, ac­cord­ing to plans re­port­ed by Bloomberg late last year. In­sid­ers had said that the com­pa­ny was look­ing to raise about $200 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.